Company Number: 13577260

Analysis Date: 2025-07-20 16:58 UTC

Financial Health Assessment: MEHAK SCENTS LTD (As at 31 August 2024)

---

1. Financial Health Score: B-

Explanation:
MEHAK SCENTS LTD shows a positive but modest financial position with net assets of £4,319 and improving shareholders’ funds over three years. The company is maintaining positive net current assets and net assets, indicating a stable but cautious financial health. However, the relatively low absolute scale of figures and the company’s young age (incorporated 2021) suggest a "developing" rather than "robust" stage of financial wellness. The score "B-" reflects a business that is solvent and growing steadily but still requires vigilance to strengthen liquidity and capital buffers.

---

2. Key Vital Signs

Metric	2024 Value	Interpretation
Current Assets	£22,171	Healthy short-term resources, increased from previous years.
Cash at Bank and in Hand	£9,696	Reasonable cash reserve, slight decrease from £10,831 in 2023.
Current Liabilities	£17,852	Manageable short-term debts, slightly increased but stable.
Net Current Assets	£4,319	Positive working capital, improving from £2,647 in 2023.
Net Assets (Shareholders’ Funds)	£4,319	Positive equity base, showing retained earnings growth.
Stocks (Inventory)	£12,475	Inventory increased, indicating active sales or stockpiling.
Profit and Loss Account Reserve	£4,219	Reflects accumulated profits, growing steadily.
Turnover / Revenue	Not disclosed	Unable to assess revenue health due to limited data.

Interpretation of Vital Signs:
The company displays a "healthy cash flow" scenario with positive net current assets, which is crucial for meeting short-term obligations. The increase in inventory suggests expanding operations or preparation for higher sales, but it also calls for careful inventory management to avoid slow-moving stock risks. The stable and growing equity base is a positive "heartbeat" indicating profitability retention.

---

3. Diagnosis: Financial Condition Overview

MEHAK SCENTS LTD is in a stable financial condition with no signs of distress. The positive net current assets and growing shareholders’ funds reflect a company that is maintaining solvency and building reserves. However, certain "symptoms" warrant attention:

• Liquidity Tightness: Although cash levels are reasonable, cash has slightly decreased, and current liabilities have increased. This suggests a potential tightening in liquid resources that needs monitoring to avoid "cash flow stress."
• Inventory Buildup: The rise in stock levels (from £8,350 in 2023 to £12,475 in 2024) could be a strategic move to meet demand or a warning sign of slow-moving inventory, which can tie up working capital.
• Limited Scale: The company remains small, consistent with its "small company" filing exemption, implying limited financial buffer against shocks.
• No Employees: The lack of employees (average zero during the year) indicates reliance on directors or contractors, which may limit operational scalability.

Overall, the company is "healthy but in a development phase," with no immediate financial distress but requiring strategic attention to liquidity and inventory management.

---

4. Recommendations for Financial Wellness Improvement

a. Strengthen Liquidity Management

• Monitor cash flow forecasts closely. Aim to increase cash reserves or secure short-term credit lines to maintain a comfortable liquidity "pulse."
• Negotiate payment terms with creditors and customers to optimise working capital cycles.

b. Inventory Control

• Conduct a detailed review of stock turnover rates to ensure inventory is not becoming obsolete or slow-moving.
• Implement just-in-time inventory practices if feasible to reduce stock holding costs.

c. Financial Reporting and Revenue Tracking

• Enhance internal financial reporting to include turnover and profitability analysis regularly, enabling earlier detection of financial "symptoms."
• Consider budgeting and variance analysis to control costs and improve margins.

d. Growth and Capital Planning

• Explore opportunities for expanding revenue streams or diversifying product offerings within the perfume and cosmetics wholesale sector.
• Consider capital injections or retained earnings reinvestment to build a more robust equity "immune system."

e. Governance and Operational Scalability

• As the company grows, consider recruiting staff or outsourcing critical functions to reduce operational bottlenecks.
• Ensure directors maintain clear oversight of financial and operational risks.

---